Insulin Price and Availability Survey in Pakistan Post-Deregulation

Encompassing survey data from 30 retail pharmacies across six regions in Pakistan, collected to evaluate the impact of a medicine price deregulation policy on insulin access. It includes post-deregulation consumer prices and availability, with pre-deregulation prices extracted from published sources, analyzed using a Difference-in-Differences (DiD) method. The data is stored in an XLSX file sized 24.9 KB.

Use Cases

• Perform Difference-in-Differences analysis to compare price changes between non-NEML insulins and NEML-listed insulins.
• Analyze the availability of insulin products, comparing originator brands (OB) and biosimilar (BS) insulins across surveyed outlets.
• Calculate the affordability of insulin for the lowest-paid worker in terms of days' wages required for a month's supply.
• Compare price trends for different insulin types, such as short-acting human biosimilar insulins versus analogue insulins.

Strengths

• Data is collected from a structured survey of 30 retail pharmacies across six regions.
• Analysis includes standardized insulin prices (10 ml at 100 IU/ml) for consistent comparison.
• The dataset supports a published policy analysis using a Difference-in-Differences methodology.

Limitations

• The dataset is small in scale at 24.9 KB, indicating limited raw data volume.
• Geographic scope is limited to six regions within Pakistan, not nationally representative.
• Pre-deregulation prices are extracted from secondary published sources, not primary collection.

Provenance

Source

Author Amna Saeed via figshare.

Collection Method

Survey of retail pharmacies using an adapted WHO/HAI approach, with pre-deregulation data from published sources.

Time Range

Pre- and post-implementation of a price deregulation policy (specific years not stated).

Freshness

Data reflects a policy analysis with a last update date of 2026-03-20.

Geography

Six regions within Pakistan.